Advancing Host-directed Therapy for Tuberculosis

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2015 Mar 14

PMID 25765201

Citations 154

Authors

Robert S Wallis

Richard Hafner

Affiliations

Soon will be listed here.

Abstract

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.

Citing Articles

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis.

Najafi-Fard S, Farroni C, Petrone L, Altera A, Salmi A, Vanini V Front Immunol. 2024; 15:1411827.

PMID: 39530101 PMC: 11550979. DOI: 10.3389/fimmu.2024.1411827.

Roles of autophagy in killing of mycobacterial pathogens by host macrophages - Effects of some medicinal plants.

Tatano Y, Shimizu T, Sano C, Tomioka H Eur J Microbiol Immunol (Bp). 2024; 14(1):26-36.

PMID: 38349363 PMC: 10895364. DOI: 10.1556/1886.2023.00062.

Relationship between metformin use and mortality in tuberculosis patients with diabetes: a nationwide cohort study.

Chung E, Jeong D, Mok J, Jeon D, Kang H, Kim H Korean J Intern Med. 2024; 39(2):306-317.

PMID: 38317270 PMC: 10918385. DOI: 10.3904/kjim.2023.303.

Immune Responses in Lung Granulomas during Mtb/HIV Co-Infection: Implications for Pathogenesis and Therapy.

Kaushal D, Singh D, Mehra S Pathogens. 2023; 12(9).

PMID: 37764928 PMC: 10534770. DOI: 10.3390/pathogens12091120.

Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection.

Nagdev P, Agnivesh P, Roy A, Sau S, Kalia N Eur J Clin Microbiol Infect Dis. 2023; 42(11):1297-1315.

PMID: 37740791 DOI: 10.1007/s10096-023-04663-0.

References

Lin H, Chu S, Wang D, Feng N . Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect. 2004; 37(1):8-15. View

Jindani A, Harrison T, Nunn A, Phillips P, Churchyard G, Charalambous S . High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 371(17):1599-608. PMC: 4233406. DOI: 10.1056/NEJMoa1314210. View

Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized,.... Arthritis Rheum. 2004; 50(5):1400-11. DOI: 10.1002/art.20217. View

Wallis R, Wang C, Meyer D, Thomas N . Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One. 2013; 8(8):e71116. PMC: 3733776. DOI: 10.1371/journal.pone.0071116. View

Yogalingam G, Pendergast A . Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J Biol Chem. 2008; 283(51):35941-53. PMC: 2602914. DOI: 10.1074/jbc.M804543200. View

Whalen C, Horsburgh C, Hom D, LaHart C, Simberkoff M, Ellner J . Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995; 151(1):129-35. DOI: 10.1164/ajrccm.151.1.7812542. View

Ogolla P, Portillo J, White C, Patel K, Lamb B, Sen G . The protein kinase double-stranded RNA-dependent (PKR) enhances protection against disease cause by a non-viral pathogen. PLoS Pathog. 2013; 9(8):e1003557. PMC: 3749959. DOI: 10.1371/journal.ppat.1003557. View

Wallis R, Broder M, Wong J, Beenhouwer D . Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004; 39(8):1254-5. DOI: 10.1086/424455. View

Wallis R, van Vuuren C, Potgieter S . Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009; 48(10):1429-32. DOI: 10.1086/598504. View

10.

. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle. 1983; 64(2):73-91. DOI: 10.1016/0041-3879(83)90032-6. View

11.

De Majumdar S, Vashist A, Dhingra S, Gupta R, Singh A, Challu V . Appropriate DevR (DosR)-mediated signaling determines transcriptional response, hypoxic viability and virulence of Mycobacterium tuberculosis. PLoS One. 2012; 7(4):e35847. PMC: 3338549. DOI: 10.1371/journal.pone.0035847. View

12.

Crampin A, Mwaungulu J, Mwaungulu F, Mwafulirwa D, Munthali K, Floyd S . Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010; 24(3):417-26. PMC: 2917772. DOI: 10.1097/QAD.0b013e32832f51cf. View

13.

Coleman M, Chen R, Lee M, Lin P, Dodd L, Maiello P . PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. 2014; 6(265):265ra167. PMC: 6413515. DOI: 10.1126/scitranslmed.3009500. View

14.

Subbian S, Bandyopadhyay N, Tsenova L, OBrien P, Khetani V, Kushner N . Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun Signal. 2013; 11:60. PMC: 3765177. DOI: 10.1186/1478-811X-11-60. View

15.

Schoeman J, Andronikou S, Stefan D, Freeman N, van Toorn R . Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol. 2010; 25(7):822-8. DOI: 10.1177/0883073809350507. View

16.

Badri M, Wilson D, Wood R . Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359(9323):2059-64. DOI: 10.1016/S0140-6736(02)08904-3. View

17.

Tan B, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa M . Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol. 2006; 177(3):1864-71. DOI: 10.4049/jimmunol.177.3.1864. View

18.

Bruns H, Stegelmann F, Fabri M, Dohner K, van Zandbergen G, Wagner M . Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J Immunol. 2012; 189(8):4069-78. PMC: 3684563. DOI: 10.4049/jimmunol.1201538. View

19.

Tobin D, Roca F, Oh S, McFarland R, Vickery T, Ray J . Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012; 148(3):434-46. PMC: 3433720. DOI: 10.1016/j.cell.2011.12.023. View

20.

Wallis R, Vinhas S, Johnson J, Ribeiro F, Palaci M, Peres R . Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis. 2003; 187(2):270-8. DOI: 10.1086/346053. View